Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546909 | 0.92 | GSR (0.42) | CPB2KISS1RKDM4AKDM4CFOLH1 | |
| SCHEMBL6856367 | 0.90 | KISS1R (0.38) | CPB2KISS1RKDM4AKDM4CFOLH1 | |
| SCHEMBL4836560 | 0.86 | SLC1A1 (0.42) | KISS1RGRIK1SLC1A2SLC1A1GRIK2 | |
| SCHEMBL16326302 | 0.86 | KISS1R (0.36) | CPB2KISS1RKDM4AKDM4CCASR | |
| SCHEMBL24642323 | 0.85 | FOLH1 (0.35) | FOLH1CASRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL24642318 | 0.85 | FOLH1 (0.35) | FOLH1CASRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL5519317 | 0.83 | FOLH1 (0.48) | FOLH1 | |
| SCHEMBL18776579 | 0.83 | CPB2 (0.32) | CPB2KISS1RFOLH1 | |
| SCHEMBL7556901 | 0.81 | SIRT6 (0.47) | CPB2FOLH1 | |
| SCHEMBL10301529 | 0.80 | CPB2 (0.38) | CPB2KISS1RKDM4AKDM4CFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522221-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | Entrada Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| EP-4359006-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | Entrada Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| EP-4337261-A2 | COMPOSITIONS AND METHODS FOR MODULATING MRNA SPLICING | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4337676-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4337263-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4314016-A1 | CYCLIC CELL PENETRATING PEPTIDES | Entrada Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2023219933-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | ENTRADA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| WO-2023081893-A1 | INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | claimed |
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | ENTRADA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | claimed |
| WO-2022271818-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | ENTRADA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | claimed |
| US-6268473-B1 | AMINO ACID SEQUENCES; MUSCLE RELAXANTS; TREATING BENIGN ESSENTIAL BLEPHAROSPASM AND OTHER FORMS OF FOCAL DYSTONIA; ANTIWRINKLE AGENTS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2001-07-31 | — | — | US | claimed |
| WO-2001035985-A1 | P-SUPERFAMILY CONOPEPTIDES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2001-05-25 | — | — | WO | claimed |
| WO-2001021648-A1 | USES OF KAPPA-CONOTOXIN PVIIA | COGNETIX, INC. (US) | 2001-03-29 | — | — | WO | claimed |
| WO-2001018033-A1 | GAMMA-CARBOXYGLUTAMATE CONTAINING CONOPEPTIDES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2001-03-15 | — | — | WO | claimed |
| WO-2000076532-A1 | νO-CONOPEPTIDES AND THEIR USE AS LOCAL ANESTHETICS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-12-21 | — | — | WO | claimed |
| WO-2000046371-A1 | TAU-CONOTOXIN PEPTIDES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-08-10 | — | — | WO | claimed |
| WO-2000044769-A1 | CONOTOXIN PEPTIDES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-08-03 | — | — | WO | claimed |
| WO-2000044776-A1 | ALPHA-CONOTOXIN PEPTIDES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-08-03 | — | — | WO | claimed |
| WO-2000043409-A2 | ALPHA-CONOTOXIN PEPTIDES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2000-07-27 | — | — | WO | claimed |
| WO-2000023092-A1 | CONTULAKIN-G, ANALOGS THEREOF AND USES THEREFOR | COGNETIX, INC. (US) | 2000-04-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027739-A1 | ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS | PRCP, TAP1, DNPEP | CPB2 60/4885KISS1R 4462/4885KDM4A 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.